Physician profile
Xiaoxin Xi
NPI 1316364599
$1,649.07
in general payments reported to CMS, 2019-2025
17 companies · $314 in 2025
The $314 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $225 · 2022: $73.62 · 2023: $374 · 2024: $663 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,350.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $232.62 | 2021-2025 | Kcentra |
| Abbvie INC. | $214.75 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $184.72 | 2021-2023 | Xarelto |
| Alexion Pharmaceuticals, INC. | $162.40 | 2023-2025 | Ultomiris |
| Pfizer INC. | $135.30 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $121.28 | 2023-2024 | Rebyota |
| Astellas Pharma US INC | $87.05 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $83.80 | 2024-2025 | Eliquis |
| Shionogi INC | $80.98 | 2023-2025 | Fetroja |
| Astrazeneca Pharmaceuticals LP | $62.13 | 2021-2023 | Lokelma |
| Merck Sharp & Dohme LLC | $60.46 | 2024 | Dificid, Zerbaxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.30 | 2021-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.11 | 2024 | Jardiance |
| Paratek Pharmaceuticals, INC. | $44.86 | 2024 | Nuzyra |
| Vifor Pharma, INC. | $42.42 | 2023 | Veltassa |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $18.36 | 2025 | |
| Melinta Therapeutics, LLC | $17.53 | 2024 | Kimyrsa, Rezzayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaoxin Xi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.